“On Wednesday, December 13, we hosted a series of investor meetings with Omnicell’s CFO, Peter Kuipers.”,” Cantor Fitzgerald’s analyst commented.
A number of other brokerages have also recently weighed in on OMCL. Zacks Investment Research cut Omnicell from a hold rating to a strong sell rating in a research note on Wednesday, November 1st. Oppenheimer reaffirmed a buy rating and issued a $55.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Craig Hallum reaffirmed a buy rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Benchmark boosted their target price on Omnicell from $55.00 to $67.00 and gave the stock a buy rating in a research note on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $55.14.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The business had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. During the same period in the previous year, the firm posted $0.40 earnings per share. The company’s revenue was up 5.7% on a year-over-year basis. research analysts anticipate that Omnicell will post 0.12 EPS for the current year.
In related news, VP Peter J. Kuipers sold 4,724 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the transaction, the vice president now directly owns 40,544 shares of the company’s stock, valued at approximately $1,935,570.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter J. Kuipers sold 3,532 shares of Omnicell stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $50.96, for a total value of $179,990.72. Following the sale, the vice president now directly owns 40,714 shares of the company’s stock, valued at $2,074,785.44. The disclosure for this sale can be found here. Insiders have sold a total of 38,944 shares of company stock valued at $1,889,592 over the last three months. 3.77% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Turner Investments LLC purchased a new stake in Omnicell during the 2nd quarter worth about $181,000. Flinton Capital Management LLC lifted its holdings in Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after buying an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after buying an additional 1,830 shares during the last quarter. Marco Investment Management LLC purchased a new stake in Omnicell during the 3rd quarter worth about $231,000. Finally, Sei Investments Co. lifted its holdings in Omnicell by 36.4% during the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after buying an additional 1,242 shares during the last quarter. 99.85% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://weekherald.com/2017/12/14/omnicells-omcl-buy-rating-reaffirmed-at-cantor-fitzgerald.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.